insulin detemir
Protein / enzyme biologic targets INSR via activation
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | LEVEMIR FLEXTOUCH | — | 2012-03-29 – 2012-05-18 | fda.gov ↗ |
| Approved | US (FDA) | LEVEMIR FLEXTOUCH | — | 2005-06-16 | fda.gov ↗ |
| Approved | EU (EMA) | Levemir | — | 2004-06-01 | europa.eu ↗ |
Trials 93 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT05134987 | Dec 2021 → May 2022 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00873223 | Mar → Sep 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00810589 | Nov → Dec 2008 | type 1 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 1 | NCT01498939 | Aug → Sep 2007 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01490099 | Aug → Nov 2006 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01498926 | Nov 2005 → Feb 2006 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01497587 | Aug → Dec 2005 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01497574 | May → Oct 2005 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01497535 | May → Oct 2004 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00760448 | Apr 2004 → Oct 2005 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01497600 | Feb → Aug 2004 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01497561 | Mar → Jun 2003 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01542450 | Aug 2002 → Feb 2003 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02162407 | Oct → Dec 1999 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05124457 | Feb 2022 → Jun 2025 overdue | gestational diabetes, type 2 diabetes mellitus | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 2 | NCT01595646 | Nov 2011 → Mar 2015 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01547169 | Mar 2011 → Dec 2012 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00764556 | May 2008 → May 2009 | chronic obstructive pulmonary disease, hyperglycemia | St George's, University of London | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02496780 | Aug 2015 → Jul 2022 | cystic fibrosis | University of Minnesota | Terminated | No outcome recorded |
| Phase 2/3 | NCT00639626 | Aug 2008 → May 2010 | cystic fibrosis-related diabetes | Nationwide Children's Hospital | Terminated | No outcome recorded |
| Phase 333 trials · 11 met primary · 1 missed | ||||||
| Phase 3 | NCT04222348 | Oct 2016 → May 2020 | gestational diabetes, perinatal disease, puerperal disorder | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Unknown | No outcome recorded |
| Phase 3 | NCT01461616 | Feb → Nov 2012 | type 1 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT01513473 | Jan 2012 → Jul 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT01100892 | Dec 2010 → Feb 2023 | cystic fibrosis, diabetes mellitus | Sydney Children's Hospitals Network | Completed | Missed primary |
| Phase 3 | NCT00856986 | Mar 2009 → Apr 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00789191 | Nov 2008 → Aug 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00623194 | Feb 2008 → Sep 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00474045 | May 2007 → Aug 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00447382 | Mar 2007 → Jul 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00435019 | Feb 2007 → Sep 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00383877 | Sep 2006 → Aug 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01709929 | Oct 2005 → Apr 2006 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00504673 | Apr 2005 → Dec 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00106366 | Mar → Dec 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00104182 | Feb 2005 → Feb 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00184600 | Nov 2004 → Aug 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00097084 | Sep 2004 → Dec 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00095082 | Sep 2004 → Dec 2005 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00184639 | Aug 2004 → Nov 2005 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00184665 | Jun 2004 → Sep 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00605137 | May 2004 → Apr 2005 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00592527 | Apr → Dec 2004 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00595374 | Dec 2003 → Oct 2004 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00605020 | Dec 2003 → Mar 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00604253 | Dec 2003 → May 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00604344 | Apr 2003 → Mar 2005 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00283751 | Mar 2003 → Nov 2004 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00604396 | Mar 2003 → Jan 2004 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00312156 | Aug 2002 → Aug 2003 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00312104 | Apr 2002 → Mar 2003 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01486940 | Mar → Oct 2002 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01697657 | Sep 2001 → Nov 2002 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT03220425 | Feb → Nov 2001 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 426 trials · 3 met primary · 3 missed | ||||||
| Phase 4 | NCT01868542 | Jun 2013 → May 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT02048189 | Mar 2012 → Feb 2015 | — | Centre Hospitalier Universitaire Dijon | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01889914 | Jan 2012 → Mar 2015 | type 2 diabetes mellitus | Centre Hospitalier Universitaire Dijon | Unknown | No outcome recorded |
| Phase 4 | NCT01654120 | Dec 2011 → Nov 2013 | type 2 diabetes mellitus | Mountain Diabetes and Endocrine Center | Completed | No outcome recorded |
| Phase 4 | NCT01486966 | Nov 2011 → Jun 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01828970 | Jan 2010 → Sep 2012 | diabetes mellitus | Centre Europeen d'Etude du Diabete | Completed | No outcome recorded |
| Phase 4 | NCT00909480 | May 2009 → Jun 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Missed primary |
| Phase 4 | NCT00795600 | Apr 2009 → Aug 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Missed primary |
| Phase 4 | NCT00862875 | Mar 2009 → Apr 2014 | type 2 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00699686 | May 2008 → Mar 2010 | cardiovascular disorder, type 2 diabetes mellitus | University of Padova | Completed | No outcome recorded |
| Phase 4 | NCT00657943 | Apr 2008 → Dec 2012 | atherosclerosis, type 2 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | Missed primary |
| Phase 4 | NCT00634842 | Feb → Oct 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 4 | NCT00607737 | Jan 2008 → Jun 2009 | diabetes mellitus | Lise Tarnow | Completed | No outcome recorded |
| Phase 4 | NCT00542399 | Nov 2007 → Jan 2010 | type 1 diabetes mellitus | Rabin Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00564395 | Aug 2007 → Dec 2009 | type 1 diabetes mellitus | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00506662 | Jul 2007 → Dec 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 4 | NCT00509925 | Jul 2007 → Jul 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 4 | NCT00346996 | May 2007 → Nov 2011 | type 1 diabetes mellitus | Lise Tarnow | Completed | Met primary |
| Phase 4 | NCT00590226 | Dec 2006 → Jan 2008 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT00521690 | Dec 2006 → Aug 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00313742 | Apr → Nov 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00490893 | Mar → Dec 2006 | diabetes mellitus, hypoglycemia | University Hospital Tuebingen | Terminated | No outcome recorded |
| Phase 4 | NCT00264901 | Oct 2005 → Nov 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00274274 | Sep 2005 → Nov 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00135070 | Jul 2005 → Jun 2006 | type 2 diabetes mellitus | The Royal Bournemouth Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00117780 | Jun 2005 → Oct 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase not applicable14 trials · 1 met primary · 1 missed | ||||||
| — | NCT06419777 | Sep 2024 → May 2026 overdue | gestational diabetes | Thomas Jefferson University | Recruiting | No outcome recorded |
| — | NCT03180281 | Jul 2017 → Jan 2020 | type 2 diabetes mellitus | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT02204839 | Jan 2014 → Jan 2015 | type 1 diabetes mellitus | Northumbria University | Completed | No outcome recorded |
| — | NCT01974544 | May 2013 → Dec 2015 | type 2 diabetes mellitus | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| — | NCT01837680 | Mar 2013 → Mar 2015 | gestational diabetes, type 2 diabetes mellitus | St. Luke's-Roosevelt Hospital Center | Completed | Met primary |
| — | NCT01232946 | Jan 2012 → Sep 2017 | type 2 diabetes mellitus | Indiana University | Completed | Missed primary |
| — | NCT01377155 | Jun → Dec 2011 | type 2 diabetes mellitus | Diabetes Care Center | Completed | No outcome recorded |
| — | NCT01239550 | Apr 2011 → Dec 2028 expected | diabetes mellitus, obesity disorder | Vanderbilt University | Active not recruiting | No outcome recorded |
| — | NCT00626080 | Jan 2009 → Dec 2011 | type 1 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT00659165 | Apr 2008 → Dec 2010 | diabetes mellitus | University of New Mexico | Completed | No outcome recorded |
| — | NCT00522210 | Mar 2008 → Mar 2011 | type 1 diabetes mellitus | University of Calgary | Completed | No outcome recorded |
| — | NCT00457093 | Oct 2006 → May 2007 | type 2 diabetes mellitus | Diabetes Care Center | Completed | No outcome recorded |
| — | NCT00564018 | Sep 2006 → Feb 2009 | type 1 diabetes mellitus | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| — | NCT00467246 | — | diabetes mellitus | The Royal Bournemouth Hospital | Withdrawn | No outcome recorded |
| Comparator or background therapy65 trials | ||||||
| Phase 1 | NCT06685185 Comparator | Nov 2024 → Mar 2026 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01135927 Comparator | Jun → Oct 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01043510 Comparator | Jan → Oct 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00652288 Comparator | Apr 2007 → Sep 2011 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00841087 Comparator | Jan → May 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04974528 Background | Sep 2021 → Oct 2024 | type 1 diabetes mellitus, type 2 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03377699 Comparator | Nov 2017 → Dec 2020 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT02131272 Comparator | Jun 2014 → Jun 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT02033889 Background | Dec 2013 → Aug 2017 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01835431 Comparator | Oct 2013 → Nov 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT01850615 Background | Sep 2013 → Nov 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT01831765 Background | Aug 2013 → May 2015 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01798706 Background | Jun 2013 → Feb 2015 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 3 | NCT01074268 Comparator | Feb → Dec 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT01003184 Comparator | Oct 2009 → Jul 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
| Phase 3 | NCT00978627 Comparator | Aug 2009 → May 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00494013 Comparator | Aug 2007 → Sep 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT00487240 Comparator | Jun 2007 → Aug 2008 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT00331604 Background | Aug 2006 → May 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00322257 Background | May 2006 → Apr 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00271284 Comparator | Oct 2005 → Sep 2008 | type 1 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 4 | NCT07112339 Comparator | Aug 2025 → Aug 2026 overdue | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 4 | NCT04416269 Comparator | Aug 2020 → Apr 2025 | type 2 diabetes mellitus | Emory University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03620890 Comparator | Sep 2018 → Jul 2020 | type 2 diabetes mellitus | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT02767596 Background | Jul 2016 → Feb 2017 | type 2 diabetes mellitus | Laniado Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02811484 Background | Jun 2016 → Jun 2018 | type 2 diabetes mellitus | Weill Medical College of Cornell University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02741687 Background | Jun 2016 → Apr 2017 | hyperglycemia | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02967211 Comparator | Dec 2015 → Oct 2017 | type 2 diabetes mellitus | Sanofi | Completed | Missed primary |
| Phase 4 | NCT02967224 Comparator | Nov 2015 → Oct 2017 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 4 | NCT02451137 Comparator | Jun 2015 → Mar 2018 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 4 | NCT01966978 Comparator | Nov 2014 → Dec 2017 | type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02219750 Comparator | Aug 2013 → Aug 2015 | type 2 diabetes mellitus | Mackay Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01440439 Comparator | Nov 2011 → Jun 2012 | type 1 diabetes mellitus | Buckinghamshire Healthcare NHS Trust | Unknown | No outcome recorded |
| Phase 4 | NCT01354925 Comparator | Sep 2011 | type 2 diabetes mellitus | Meir Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01269034 Comparator | Dec 2010 → Jan 2017 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01232491 Background | Oct 2010 → Nov 2011 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01165684 Background | Oct 2010 → Apr 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01068652 Comparator | Mar 2010 → May 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00906529 Comparator | May 2009 → Dec 2010 | type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT00717288 Comparator | Jul 2008 → Mar 2010 | diabetes mellitus | Ohio State University | Completed | No outcome recorded |
| Phase 4 | NCT00742976 Comparator | Jun 2008 → Dec 2009 | type 2 diabetes mellitus | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT00591227 Comparator | May 2008 → Jul 2009 | type 2 diabetes mellitus | Rush University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00941148 Comparator | Apr 2008 → Mar 2009 | diabetes mellitus, noninsulin-dependent, 2 | ikfe-CRO GmbH | Completed | No outcome recorded |
| Phase 4 | NCT01076842 Comparator | Apr 2008 → Apr 2011 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00788840 Comparator | Jan 2008 → Aug 2009 | obesity disorder, type 2 diabetes mellitus | University of Surrey | Completed | No outcome recorded |
| Phase 4 | NCT00455858 Comparator | Nov 2007 → Oct 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00537303 Background | Oct 2007 → Mar 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00542620 Comparator | Sep 2007 → Mar 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00998335 Comparator | Jun 2007 → Feb 2010 | type 2 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00467649 Background | May 2007 → Apr 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
| Phase 4 | NCT00405418 Comparator | Nov 2006 → Jun 2008 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 4 | NCT01271517 Comparator | Sep 2005 → Mar 2011 | type 1 diabetes mellitus | Karolinska Institutet | Unknown | No outcome recorded |
| Phase 4 | NCT00566124 Comparator | Jan → May 2005 | diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00747409 Comparator | Jul 2004 → Mar 2009 | type 2 diabetes mellitus | Munich Municipal Hospital | Unknown | No outcome recorded |
| — | NCT06419803 Comparator | Sep 2024 → May 2026 overdue | gestational diabetes | Thomas Jefferson University | Recruiting | No outcome recorded |
| — | NCT04965051 Comparator | Aug 2021 → Dec 2023 | type 1 diabetes mellitus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT03001323 Comparator | Jan 2017 → Jan 2019 | diabetes mellitus | Hennepin Healthcare Research Institute | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02846233 Comparator | Aug 2016 → Dec 2018 | type 2 diabetes mellitus | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT02824510 Comparator | Aug 2014 → Sep 2016 | type 1 diabetes mellitus | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| — | NCT02155023 Background | Jan 2014 → Jan 2015 | diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| — | NCT01310452 Comparator | Jan 2011 → ? | type 2 diabetes mellitus | Fudan University | Unknown | No outcome recorded |
| — | NCT01186003 Comparator | Aug 2010 → May 2014 | diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01420692 Comparator | Jun 2010 → Apr 2012 | type 2 diabetes mellitus | Ankara University | Completed | No outcome recorded |
| — | NCT01022658 Comparator | Jan 2010 → Jul 2011 | type 2 diabetes mellitus | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2012-06-09 | Alkermes, Inc. | Results Once-Weekly BYDUREON™ Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir® in Type 2 Diabetes alkermes.com ↗
Treatment with BYDUREON also resulted in greater improvement in A1C (-1.3 percentage points) than insulin detemir (-0.88 percentage points). |
| 2005-06-16 | Novo Nordisk A/S | Regulatory Novo Nordisk receives US approval of Levemir® and becomes the first company with a full range of insulin analogues in the US novonordisk.com ↗
Novo Nordisk announced today that the US Food and Drug Administration (FDA) has granted marketing authorisation for Levemir®, the company's long-acting insulin analogue for the treatment of diabetes. |
| 2005-06-16 | Novo Nordisk A/S | Regulatory Novo Nordisk opnår FDA-godkendelse af Levemir® og kan dermed som de første tilbyde et fuldt sortiment af insulinanaloger i USA novonordisk.com ↗
Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder (FDA) har givet tilladelse til markedsføring af den langtidsvirkende insulinanalog Levemir® til behandling af diabetes. |
All press releases naming this drug 3 releases
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 180 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin detemir | “A Randomised, Open-labelled, Single-centre, Two-period Crossover Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single s.c. Doses of NN304 (Insulin Detemir)...” NCT01542450 ↗120“OBJECTIVE: We sought to determine if insulin detemir (IDet) is noninferior to insulin neutral protamine Hagedorn (NPH) for the treatment of gestational diabetes mellitus (GDM)...” PMID 26070699 ↗ Jun 2015 “Treatment with insulin detemir and aspart in patients with type 1 diabetes and recurrent severe hypoglycaemia resulted in a clinically significant reduced rate of severe...” PMID 24794703 ↗ May 2014 “The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for...” NCT07112339 ↗ “We performed a non-inferiority trial comparing insulin detemir (Levemir) and biphasic insulin (NovoMix70) to standard care during Ramadan fast in insulin treated type 2...” PMID 26234442 ↗ Jul 2015 “Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.” NCT01850615 ↗ “AIMS: The efficacy of two basal insulins, insulin lispro protamine suspension (ILPS) and insulin detemir, was compared in basal-bolus regimens in Type 1 diabetes.” PMID 20536953 ↗ May 2010 “BACKGROUND: Insulin detemir, being used increasingly during pregnancy, may have pharmacologic benefits compared with neutral protamine Hagedorn.” PMID 33865836 ↗ Apr 2021 “This protocol addresses a comparison of insulin glargine and insulin detemir for patients evaluated by CGMS.” NCT00457093 ↗ “Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient.” NCT04974528 ↗ “During this arm/phase, patients take insulin Detemir subcutaneously for 3 months.” NCT00699686 ↗ |
| Known as | B29Lys(epsilon-tetradecanoyl),desB30 human insulin | “We compared the symptoms of hypoglycaemia induced by insulin detemir (NN304) (B29Lys(epsilon-tetradecanoyl),desB30 human insulin) and equally effective doses of neutral...” PMID 19707744 ↗ Aug 2009 |
| Known as | B29Lys(ε-tetradecanoyl),desB30 human insulin | “insulin detemir (B29Lys(ε-tetradecanoyl),desB30 human insulin)” PMID 22002075 ↗ Oct 2011 |
| Known as | detemir | “This 52-week multinational, randomised, open-label, parallel-group, non-inferiority trial compared clinical outcomes following supplementation of oral glucose-lowering drugs...” PMID 18204830 ↗ Jan 200834“Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of participant's home insulin regimen at the...” NCT03001323 ↗ “Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination...” NCT01068652 ↗ “To assess weight change when once-daily insulin detemir (detemir) or neutral protamine Hagedorn insulin (NPH) are used in already overweight Type 2 diabetes patients requiring...” PMID 18959604 ↗ Aug 2008 “Used this way, the insulin analogue detemir has been associated with improved glycemic control of a magnitude similar to neutral protamine Hagedorn (NPH), with lower rates of...” PMID 17157113 ↗ Oct 2006 “Insulin detemir (detemir) has previously been shown to be associated with lower within-subject variability compared with other basal insulin preparations in adults with type 1...” PMID 18761644 ↗ Aug 2008 “AIMS: This study assessed the efficacy and safety of once-daily insulin initiation using insulin detemir (detemir) or insulin glargine (glargine) added to existing metformin in...” PMID 23421331 ↗ Mar 2013 “slow-acting insulin detemir mixed with aspart would have equivalent effects on blood glucose versus giving them as separate injections in children with type 1 diabetes.” NCT00564395 ↗ “Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.” NCT01798706 ↗ “insulin detemir (detemir) was noninferior to insulin glargine (glargine) as the basal insulin” PMID 19922879 ↗ Oct 2009 “basal-bolus therapy with insulin detemir (detemir), a new soluble basal insulin analogue” PMID 16842476 ↗ Jul 2006 |
| Known as | IDet | “OBJECTIVE: This randomized, controlled noninferiority trial aimed to compare the efficacy and safety of insulin detemir (IDet) versus neutral protamine Hagedorn (NPH) (both...” PMID 22851598 ↗ Jul 20129“The aim of this trial was to evaluate the efficacy and safety of the combination of once-daily insulin detemir (IDet) and sitagliptin (SITA) versus SITA ± sulphonylurea (SU),...” PMID 21205123 ↗ Mar 2011 “Patients were randomized 1:1 (age stratified: 1-<6 years; 6-<12 years; 12-<18 years) to IDegAsp once daily (OD) plus insulin aspart (IAsp) for remaining meals (IDegAsp + IAsp),...” PMID 30014589 ↗ Aug 2018 “This randomised (1:1), multinational, open-labelled, parallel group trial compared insulin detemir (IDet) with neutral protamine Hagedorn (NPH) insulin, in combination with...” PMID 21418455 ↗ Mar 2011 “OBJECTIVE: We sought to determine if insulin detemir (IDet) is noninferior to insulin neutral protamine Hagedorn (NPH) for the treatment of gestational diabetes mellitus (GDM)...” PMID 26070699 ↗ Jun 2015 “To evaluate efficacy and tolerability of a co-formulation of insulin degludec and insulin aspart (IDegAsp) with insulin aspart (IAsp) at other meals compared with basal-bolus...” PMID 22933438 ↗ Aug 2012 “The efficacy and safety of insulin degludec (IDeg) was compared with insulin detemir (IDet), both administered once daily (OD) as basal treatment in participants with type 1...” PMID 24702700 ↗ May 2014 “This treat-to-target study compared the efficacy and safety of insulin detemir (IDet) and insulin glargine (IGla) in a basal-bolus (insulin aspart) regimen in type 2 diabetes.” PMID 19565569 ↗ Sep 2009 “Insulin degludec (IDeg) once-daily was compared with insulin detemir (IDet) once- or twice-daily” PMID 25683037 ↗ Feb 2015 “the long-acting insulin analogues insulin detemir (IDet) and NPH insulin (NPH)” PMID 16918592 ↗ Sep 2006 |
| Known as | Ins levemir | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104391 ↗ |
| Known as | Insulin detemir recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104391 ↗ |
| Known as | insulin Detemir: Levemir | “insulin detemir (Levemir)” NCT00000620 ↗1“insulin Detemir: Levemir” NCT01461616 ↗ |
| Known as | Insulin Levemir | “Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks” NCT00487240 ↗ |
| Known as | Insulin,detemir,human | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104391 ↗ |
| Known as | Insulina detemir | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104391 ↗ |
| Known as | Insuline detemir | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104391 ↗ |
| Known as | Levemir | “We performed a non-inferiority trial comparing insulin detemir (Levemir) and biphasic insulin (NovoMix70) to standard care during Ramadan fast in insulin treated type 2...” PMID 26234442 ↗ Jul 201522“Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks.” NCT01232491 ↗ “the patient will receive an additional injection of basal insulin LEVEMIR® : five injections per day” NCT01889914 ↗ “Participants will get insulin NNC0363-0845 as well as insulin detemir (Levemir®).” NCT05134987 ↗ “basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])” NCT00467649 ↗ “(Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk)” NCT02204839 ↗ “Levemir/Lantus/Tresiba plus NovoLog/Humalog/Apidra” NCT04965051 ↗ “Levemir, durg class: long-acting insulin” NCT02219750 ↗ “Lantus, Levemir, Novolog, Lispro” NCT02811484 ↗ “Lantus, Toujeo, NPH, levemir” NCT02846233 ↗ “Levemir® (insulin detemir)” NCT01868542 ↗ |
| Known as | levemir insulin | “Drug: levemir insulin” NCT02496780 ↗ |
| Known as | NN304 | “A Randomised, Open-labelled, Single-centre, Two-period Crossover Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single s.c. Doses of NN304 (Insulin Detemir)...” NCT01542450 ↗2“A 48-week, Randomised, Multi-centre, Openlabelled, Parallel-group Trial to Compare the Efficacy and the Safety of NN304 (Insulin Detemir) and NPH Human Insulin in Subjects With...” NCT00604344 ↗ “We compared the symptoms of hypoglycaemia induced by insulin detemir (NN304) (B29Lys(epsilon-tetradecanoyl),desB30 human insulin) and equally effective doses of neutral...” PMID 19707744 ↗ Aug 2009 |
| Action | Activate | “enhanced signaling through the insulin receptor” NCT01239550 ↗1“Insulin receptor agonist” CHEMBL2104391 ↗ |
| Modality | Protein / enzyme biologic | “subcutaneous insulin analogues” NCT00135070 ↗ |
| Route | Subcutaneous | “evening SC injection of detemir” PMID 17157113 ↗ Oct 2006 |
| Target | INSR | “Insulin receptor agonist” CHEMBL2104391 ↗ |